Diverse Clinical manifestations of Cobalamin C Metabolism Disorders
Iranian Journal of Child Neurology,
Vol. 19 No. 2 (2025),
11 March 2025
,
Page 131-141
https://doi.org/10.22037/ijcn.v19i2.45047
Abstract
Cobalamin, commonly known as vitamin B12, is a crucial micronutrient synthesized predominantly by a few microorganisms. In the human body, Vitamin B12 (Cobalamin) is essential for DNA synthesis and is required as a cofactor for functioning two crucial enzymes, methylmalonyl-CoA mutase and methionine synthase. The deficiency in these cobalamin-derivated coenzymes leads to enzyme activity dysfunction and an accumulation of their respective substrates, methylmalonic acid, and homocysteine,harming the brain and many other organs. Furthermore, deficiency in this micronutrient can lead to a wide spectrum of hematologic and neuropsychiatric disorders. In addition to vitamin B12 deficiency, some genetic disorders block the intracellular processing of Cobalamin to its cofactors and lead to symptoms somewhat similar to vitamin B12 deficiency. These disorders are called Cobalamin metabolism disorders. Many of them are reversible when diagnosed early and treated promptly. This group’s most common and well-understood disease is Cobalamin C (CblC) metabolism disorder. This case series report aimed to provide a comprehensive overview of diverse clinical presentations within the spectrum of CblC metabolism disorder and the introduction of two cases of late-onset presentation with ataxia and repeated seizures as the first manifestation of the disorder. Few case reports are available, specifically in children, describing cerebellar ataxia and seizure as the first manifestations of late-onset CblC metabolism disorder. Additionally, this report sought to contribute to the existing literature by highlighting potential areas for timely recognition and targeted clinical and therapeutic interventions, thereby enhancing the comprehensive care and support for individuals affected by CblC metabolism disorder
- Cobalamin-C methylmalonic academia
- homocystinuria
- Cerebellar Ataxias
- Epilepsies
- Hydroxycobalamin
How to Cite
References
O'Leary F, Samman S. Vitamin B12 in health and disease. Nutrients. 2010;2(3):299-316.
Ben‐Omran TI, Wong H, Blaser S, Feigenbaum A. Late‐onset cobalamin‐C disorder: a challenging diagnosis. American Journal of Medical Genetics Part A. 2007;143(9):979-84.
Rickes EL, Brink NG, Koniuszy FR, Wood TR, Folkers K. Crystalline vitamin B12. Science. 1948;107(2781):396-7.
Scott JM, Molloy AM. The discovery of vitamin B(12). Annals of nutrition & metabolism. 2012;61(3):239-45.
Mascarenhas R, Gouda H, Ruetz M, Banerjee R. Human B(12)-dependent enzymes: Methionine synthase and Methylmalonyl-CoA mutase. Methods in enzymology. 2022;668:309-26.
Wolffenbuttel BHR, Wouters H, Heiner-Fokkema MR, van der Klauw MM. The Many Faces of Cobalamin (Vitamin B(12)) Deficiency. Mayo Clinic proceedings Innovations, quality & outcomes. 2019;3(2):200-14.
Sobczyńska-Malefora A, Delvin E, McCaddon A, Ahmadi KR, Harrington DJ. Vitamin B12 status in health and disease: a critical review. Diagnosis of deficiency and insufficiency – clinical and laboratory pitfalls. Critical Reviews in Clinical Laboratory Sciences. 2021;58(6):399-429.
Froese DS, Gravel RA. Genetic disorders of vitamin B₁₂ metabolism: eight complementation groups--eight genes. Expert reviews in molecular medicine. 2010;12:e37.
Coelho D, Suormala T, Stucki M, Lerner-Ellis JP, Rosenblatt DS, Newbold RF, et al. Gene identification for the cblD defect of vitamin B12 metabolism. The New England journal of medicine. 2008;358(14):1454-64.
Ahrens-Nicklas RC, Serdaroglu E, Muraresku C, Ficicioglu C. Cobalamin C Disease Missed by Newborn Screening in a Patient with Low Carnitine Level. JIMD reports. 2015;23:71-5.
Ahrens-Nicklas RC, Whitaker AM. Efficacy of early treatment in patients with cobalamin C disease identified by newborn screening: a 16-year experience. 2017;19(8):926-35.
Almannai M, Marom R, Divin K, Scaglia F, Sutton VR, Craigen WJ, et al. Milder clinical and biochemical phenotypes associated with the c.482G>A (p.Arg161Gln) pathogenic variant in cobalamin C disease: Implications for management and screening. Molecular genetics and metabolism. 2017;122(1-2):60-6.
Brooks BP, Thompson AH, Sloan JL, Manoli I, Carrillo-Carrasco N, Zein WM, et al. Ophthalmic Manifestations and Long-Term Visual Outcomes in Patients with Cobalamin C Deficiency. Ophthalmology. 2016;123(3):571-82.
Lerner-Ellis JP, Tirone JC, Pawelek PD, Doré C, Atkinson JL, Watkins D, et al. Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC type. Nature genetics. 2006;38(1):93-100.
- Abstract Viewed: 166 times